Health & Biotech
Check out the latest news, insights and unique analysis brought to you by Stockhead's team of business journalists and industry experts on Neurizon Therapeutics.
RELATED STOCKHEAD STORIES
News
Closing Bell: ASX climbs as miners flex; US SEC eases up on crypto crackdown
Health & Biotech
Neurizon granted US patent for lead drug to treat motor neurone and other neurodegenerative conditions
Health & Biotech
Health Kick Podcast: Neurizon gears up for big year in tackling ALS
Health & Biotech
Stocking stuffers: Morgans’ top ASX health picks for 2025
Health & Biotech
Scott Power: Which stock fell off its perch on poor trial results this week?
Health & Biotech
In big news week Neurizon secures key orphan status for motor neurone drug in Europe
Health & Biotech
Neurizon files key IND application with US FDA for motor neurone disease drug
Health & Biotech
Health Check: It’s a wipe out! Percheron shares tumble up to 91pc on rare genetic disease trial failure
Health & Biotech
Positive interim study results for Neurizon’s motor neurone disease drug
Health & Biotech
Health Check: Can Syntara produce the next multibillion-dollar Aussie blood cancer drug?
Health & Biotech
Preclinical studies confirm potential of Neurizon’s lead drug to treat ALS
Health & Biotech
Scott Power: S&P/ASX 200 Health Care Index falls but which stocks are up on positive news?
Health & Biotech
NUZ inks positive opinion on orphan product designation for NUZ-001 in Europe
Health & Biotech
Spark Plus sees 225pc upside in biotech player Neurizon
Health & Biotech
Neurizon’s strong September quarter to propel treatments for neurodegenerative diseases forward
Stockhead TV
Long Shortz with Neurizon Therapeutics: Goodbye to PharmAust, hello to neuro horizons
Health & Biotech